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Abstract
Purpose: In June 2013 a European Medicines Agency referral procedure concluded
that diclofenac was associated with an elevated risk of acute cardiovascular events
and contraindications, warnings, and changes to the product information were
implemented across the European Union. This study measured the impact of the reg-
ulatory action on the prescribing of systemic diclofenac in Denmark, The Nether-
lands, England, and Scotland.
Methods: Quarterly time series analyses measuring diclofenac prescription initiation,
discontinuation and switching to other systemic nonsteroidal anti-inflammatory
(NSAIDs), topical NSAIDs, paracetamol, opioids, and other chronic pain medication in
those who discontinued diclofenac. Absolute effects were estimated using inter-
rupted time series regression.
Results: Overall, diclofenac prescription initiations fell during the observation periods
of all countries. Compared with Denmark where there appeared to be a more limited
effect, the regulatory action was associated with significant immediate reductions in
diclofenac initiation in The Netherlands (−0.42%, 95% CI, −0.66% to −0.18%),
England (−0.09%, 95% CI, −0.11% to −0.08%), and Scotland (−0.67%, 95% CI,
−0.79% to −0.55%); and falling trends in diclofenac initiation in the Netherlands
(−0.03%, 95% CI, −0.06% to −0.01% per quarter) and Scotland (−0.04%, 95% CI,
−0.05% to −0.02% per quarter). There was no significant impact on diclofenac dis-
continuation in any country. The regulatory action was associated with modest dif-
ferences in switching to other pain medicines following diclofenac discontinuation.
Conclusions: The regulatory action was associated with significant reductions in
overall diclofenac initiation which varied by country and type of exposure. There was
no impact on discontinuation and variable impact on switching.
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1 | INTRODUCTION
Adverse effects from medicines are common, and improving the safe
use of medicines requires effective communication of new safety
information. Regulatory agencies such as the European Medicines
Agency (EMA) and the US Food and Drug Administration (FDA) con-
stantly evaluate the benefit and risk of a medicine and are responsi-
ble for alerting prescribers and patients to new safety information.
Despite regulatory decisions having the enormous potential to
affect public health, their impact is often poorly understood and can
vary.1
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as
diclofenac, are widely prescribed agents for the management of
pain, fever, and inflammatory conditions.2 In June 2013, an EMA
referral procedure examined the cardiovascular safety of diclofenac
based upon evidence from available randomised controlled trials and
observational studies.3-5 The referral procedure concluded that
although diclofenac-containing medicines are effective treatments
for their approved indications, systemic formulations of diclofenac
were associated with an elevated risk of acute cardiovascular
events. The referral procedure also concluded that for the benefit-
risk balance of diclofenac to remain favourable, contraindications,
warnings, and changes to the product information, including com-
munication via a direct health care professional communication
(DHPC) were required to be implemented across the European
Union (EU).
The main elements of the risk minimisation measures were that
diclofenac should be used at the lowest dose for the shortest duration
possible, and use be contraindicated and cautioned in certain patient
groups6 In order to evaluate the impact of the risk minimisation mea-
sures, the EMA commissioned a study to examine potential changes
in various aspects of diclofenac prescribing that may have occurred
across several EU countries including a detailed overview of
diclofenac initiation, discontinuation, switching to other treatments,
and how these were influenced by age, gender, and indication. The
aim of this study was therefore to evaluate the impact of the EMA risk
minimisation measures implemented in 2013 on overall diclofenac
prescription initiation, discontinuation, and switching to other pre-
scribed pain medication in Denmark, The Netherlands, England, and
Scotland.
2 | METHODS
2.1 | Data sources
Four validated population data sources were analysed (see supple-
mentary methods for details). In brief, these were the following:
• The United Kingdom Clinical Practice Research Datalink (CPRD)
that contains primary care data. For this analysis, we used only up-
to-standard data from non-Scottish practices (encompassing
England, Wales, and Northern Ireland—henceforth, referred to as
“England”) with the majority (approximately 90%) being from
England.7
• The Scottish Prescribing Information System (PIS) that records all
medicines dispensed from pharmacies in Scotland that can be
record-linked to demographic data, Scottish Morbidity Records,
and death registrations for the entire population.8
• The Danish Register of Medicinal Products that records all out-of-
hospital prescriptions and allows linkage of drug exposures to inpa-
tient and outpatient hospital contacts and death data.9-11
• The Dutch PHARMO Database Network combines data from
primary and secondary health care settings in The Netherlands.
These different data sources, including data from general prac-
tices, in- and out-patient pharmacies, clinical laboratories, hos-
pitals, the cancer registry, pathology registry and perinatal
registry, are linked on a patient level through validated
algorithms.12
2.2 | Study population
Cohorts were generated to provide aggregate time series data for
analysis using a common protocol (EU PAS Register number
EUPAS24089).13 The study start period varied by the availability
of data from each database. For each country, data were avail-
able for 2007Q1 to 2018Q1 in Denmark; 2008Q2 to 2016Q4 in
The Netherlands; 2007Q1 to 2018Q1 in England; and 2010Q3 to
2017Q4 in Scotland. All patients were required to have at least
1 year of observation (lookback period) prior to inclusion in the
cohort. Cohort entry was defined within each data source by the
date of registration with the general practice (in CPRD and
PHARMO data sources) or date of first recorded prescription or
any secondary care diagnosis (in Danish and Scottish data
sources). A patient's index date was the latest of the study period
start date, the date of birth, or their first database follow up date
plus 1 year (to allow sufficient time to determine prevalent ver-
sus incident use of medicines). A patient's last follow up date was
the first occurrence of the following: death (all databases); end of
study period (which varied between countries); and end of regis-
tration (end of registration would not significantly affect data
from Denmark and Scotland because they use national data that
captures patients moving within the health system). A patient
was included in the time period aggregate if the first and last day
both lay between the patient's index date and their last follow up
date, so patients were observable for the entire quarter.
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2.3 | Exposures
The study population consisted of patients with the exposures listed
below (see supplementary methods for full definition). These were
analysed as a series of proportions from aggregated patient counts
evaluated in each quarter over the study period.
• Diclofenac prescribing initiation overall
• Diclofenac prescribing initiation by indication, age, gender, and
exposure type
• Diclofenac prescribing discontinuation overall
• Switching patterns to other prescribed pain medicines following
diclofenac discontinuation
Exposure type was defined as one-off use, sporadic use or chronic
use, and we also calculated the mean prescription duration for diclofenac
(please see supplementary methods for further details of definitions).
2.4 | Outcome
The outcome of interest evaluated was any immediate change in pre-
scribing at the date of the regulatory action (pre-specified as June
2013, 2013Q2) and/or change in prescribing trend postintervention
compared with the baseline prescribing trend.
2.5 | Study design and statistical analysis
The study design was an interrupted time series regression analysis of
prescribing trends. The primary analysis used interrupted time series
regression to fit quarterly time trends for each country. The effect of
the intervention for each country was represented either by a step
function or by a continuous linear function modelling the baseline
slope before the intervention time point, the change in slope from
the baseline trend to the post-intervention trend, and the immediate
change associated with the intervention time point as described by
Wagner et al.14 Before fitting all regression models, the data were
visualised graphically. The range of data points was trimmed to
periods immediately before and after June 2013 where trends were
approximated to be linear when discontinuities occurred. Trends
were modelled using weighted linear regression, the weights being
the denominators in each proportion. All models were checked for
autocorrelation using the Durbin-Watson statistic. All analyses were
carried out using SAS V9.4. Please see supplementary methods for
further details.
2.6 | Ethical permissions
Permission to conduct the study in each database was obtained from
the relevant source from each country, according to each database's
standard terms and conditions.
3 | RESULTS
The overall cohorts consisted of approximately 5.6 million in Den-
mark, approximately 5.3 million in Scotland, approximately 4.2 million
in England, Wales and Northern Ireland, and approximately 1 million
in The Netherlands. The quarterly prevalence of diclofenac initiation
at the start and end of each data source follow-up ranged from 0.98%
in Denmark to 2.47% in the Netherlands (Table S1).
3.1 | Impact of the 2013 EMA intervention on
diclofenac initiation
Results of overall diclofenac initiation per country are shown in
Figure 1 and Table 1. In Denmark, the Netherlands, and Scotland,
there was no trend in diclofenac initiation before the regulatory
action, whilst in England, the trend was negative. In England, The
Netherlands, and Scotland, the regulatory action was
associated with a significant immediate fall in diclofenac
initiation (Table 1). Postintervention, diclofenac initiation fell less
steeply in England, began to significantly fall in The Netherlands
and in Scotland (Table 1). The regulatory action was not associ-
ated with a significant change in diclofenac initiation overall in
Denmark.
3.2 | Impact on diclofenac initiation stratified by
indication, age, gender, and exposure type
Trends in diclofenac initiation per country by indication, age, gender,
and exposure type are shown in Figures S1 to S4. The most common
indication for diclofenac in all countries was osteoarthritis. Diclofenac
initiation was greater in women than men and consisted mostly of
one-off use. In Denmark, the regulatory action was associated with a
significant immediate fall in diclofenac initiation in people with osteo-
arthritis and change to a negative trend in people with osteoarthritis
and inflammatory arthropathies compared with baseline (Table S2). In
The Netherlands, the regulatory action was associated with a
Key points
• Diclofenac initiation fell following the 2013 EMA regula-
tory action that varied by country
• EMA regulatory action had a greater effect on diclofenac
initiation than discontinuation
• EMA regulatory action was associated with modest dif-
ferences in switching to other pain medicines
• In Scotland, the EMA regulatory action was associated
with an increase in switching to opioids
• Further research is required to better understand varia-
tion in the impact of regulatory actions
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significant immediate fall in people with osteoarthritis and inflamma-
tory arthropathies, and change to a negative trend for all indications
compared with baseline (Table S3). In England and Scotland, the regu-
latory action was associated with a significant immediate fall for all
indications (Tables S4 and S5). When considering all countries, the
regulatory action tended to have a greater effect among older
patients. In Denmark, it was associated with significant immediate falls
and change to a negative trend for chronic use only, compared with
England where significant changes were observed with one-off use
and chronic use and in the Netherlands and Scotland where it signifi-
cantly affected all types of use.
3.3 | Impact of the 2013 EMA intervention on
diclofenac discontinuation
The results for diclofenac discontinuation per country are shown in
Figure 2 and Table 1. The pre-intervention baseline trend in diclofenac
F IGURE 1 Trends in diclofenac initiation in Denmark, the Netherlands, England, and Scotland
TABLE 1 Interrupted time series regression results for trends in overall diclofenac initiation and discontinuation in each country
Trends in Diclofenac Initiation and Discontinuation Rates (%/quarter)
Before June 2013
Change in first quarter after
June 2013 Change after June 2013
Initiation overall
Denmark 0.006 (−0.014, 0.026), P = .534 −0.038 (−0.096, 0.020), P = .183 −0.014 (−0.034, 0.006), P = .156
Englanda −0.019 (−0.022, −0.016), P = <.001 −0.093 (−0.109, −0.077), P = <.001 0.013 (0.009, 0.016), P = <.001
Netherlands 0.000 (−0.016, 0.016), P = .970 −0.417 (−0.658, −0.175), P = .001 −0.029 (−0.057, −0.001), P = .041
Scotland 0.008 (−0.006, 0.022), P = .240 −0.671 (−0.790,-0.552), P = <.001 −0.039 (−0.054, −0.023), P = <.001
Discontinuation overall
Denmark −0.033 (−0.171, 0.105), P = .633 −0.680 (−4.889, 3.529), P = .745 0.251 (−0.221, 0.722), P = .288
Englanda −1.309 (−1.915, −0.704), P = <.001 2.186 (−1.438, 5.809), P = .224 0.456 (−0.210, 1.122), P = .170
Netherlands −0.334 (−0.499, −0.170), P = <.001 0.797 (−1.957, 3.551), P = .559 0.108 (−0.233, 0.449), P = .522
Scotland 0.403 (0.049, 0.757), P = .027 2.413 (−1.077, 5.903), P = .167 −0.932 (−1.383, −0.482), P = <.001
aApproximately 10% patients were from Northern Ireland and Wales.
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discontinuation was falling in England and The Netherlands, rising in
Scotland, and flat in Denmark. The regulatory action was not associ-
ated with a significant immediate change in discontinuation or a sig-
nificant change in trend in Denmark, England, or The Netherlands.
In Scotland, the regulatory action was associated with a change
from a significantly rising trend to a falling trend in diclofenac
discontinuation.
3.4 | Impact of the 2013 EMA intervention on
switching
In Denmark, the baseline trend was rising for switching to other pain
medicine groups apart from topical NSAID prescribing that had been
falling (Figure 3 and Table 2). The regulatory action was associated
with a significant immediate rise in switching to paracetamol (5.92%,
95% CI, 4.07% to 7.77%), and significant immediate fall in switching
to opioids (−1.28%, 95% C,I −2.27% to −0.29%) and other chronic
pain medication (−0.51%, 95% CI, −0.81% to −0.20%). Compared
with baseline, the regulatory action was associated with a significant
rising trend in switching to paracetamol and topical NSAIDs and a fall-
ing trend in switching to opioids (Table 2). There was no significant
change in trend for switching to other systemic NSAIDs or chronic
pain medication compared with baseline.
In The Netherlands, the baseline trend was rising for switching to
topical NSAIDs, paracetamol, and other chronic pain medication;
falling for other systemic NSAIDs; and flat for opioids (Figure 4 and
Table 2). The regulatory action was not associated with any immediate
change or change in trend in switching for any group. In England, the
baseline trend in switching to other pain medicine groups was rising
(Figure 5 and Table 2). The regulatory action was associated with a
significant immediate rise in switching to other systemic NSAIDs and
other chronic pain medication. Compared with baseline, there was a
significant falling trend in switching to all groups following the regula-
tory action apart for switching to topical NSAIDs that remained
unchanged. In Scotland, the baseline trend was flat for switching to
other pain medicine groups (Figure 6 and Table 2). The regulatory
action was associated with a significant immediate rise in switching to
other pain medicine groups and a significantly increasing trend in
switching to opioids. In contrast, there were significant falling trends
in switching to other systemic NSAIDs and to paracetamol (Table 2).
4 | DISCUSSION
The 2013 EMA regulatory action for diclofenac had a significant
impact on diclofenac prescribing the magnitude and type of which
varied between countries. Although the rate of diclofenac initiation
fell in all four countries throughout the entire observation period, the
2013 regulatory action for diclofenac was not associated with signifi-
cant falls in overall diclofenac initiation in Denmark compared with
The Netherlands, England, and Scotland. However, it was associated
F IGURE 2 Trends in diclofenac discontinuation in Denmark, the Netherland, England, and Scotland
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F IGURE 3 Trends in switching to other pain medicines in Denmark
TABLE 2 Interrupted time series regression results for trends in switching to alternative medicines
Trends in Diclofenac Initiation Rates (%/quarter)
Before June 2013 Change in first quarter after June 2013 Change after June 2013
Denmark
Other systemic NSAIDs 0.091 (0.012, 0.171), P = .025 −0.311 (−2.645, 2.022), P = .789 −0.083 (−0.301, 0.134), P = .443
Topical NSAIDs −0.004 (−0.005, −0.003), P = <.001 −0.004 (−0.039, 0.030), P = .803 0.007 (0.003, 0.010), P = <.001
Paracetamol 0.092 (0.029, 0.155), P = .005 5.920 (4.071, 7.769), P = <.001 0.429 (0.257, 0.601), P = <.001
Opioids 0.134 (0.100, 0.167), P = <.001 −1.279 (−2.266,-0.293), P = .012 −0.131 (−0.222, −0.039), P = .006
Other chronic pain medicines 0.095 (0.085, 0.106), P = <.001 −0.506 (−0.808,-0.203), P = .002 0.009 (−0.019, 0.037), P = .517
The Netherlands
Other systemic NSAIDs −0.013 (−0.018, −0.009), P = <.001 0.050 (−0.024, 0.124), P = .176 -0.009 (−0.018, 0.000), P = .060
Topical NSAIDs 0.002 (0.001, 0.003), P = .003 −0.017 (−0.038, 0.005), P = .125 0.001 (−0.001, 0.004), P = .366
Paracetamol 0.006 (0.000, 0.011), P = .043 −0.015 (−0.110, 0.080), P = .753 0.001 (−0.010, 0.013), P = .849
Opioids 0.015 (−0.033, 0.063), P = .525 −0.250 (−1.058, 0.558), P = .534 0.052 (−0.047, 0.151), P = .290
Other chronic pain medicines 0.008 (0.003, 0.014), P = .004 0.037 (−0.054, 0.129), P = .413 0.008 (−0.004, 0.019), P = .174
Englanda
Other systemic NSAIDs 0.133 (0.108, 0.159), P = <.001 1.509 (0.217, 2.801), P = .023 −0.325 (−0.476, −0.174), P = <.001
Topical NSAIDs 0.005 (0.002, 0.008), P = .001 0.043 (−0.105, 0.191), P = .562 −0.014 (−0.031, 0.004), P = .121
Paracetamol 0.021 (0.015, 0.026), P = <.001 0.251 (−0.036, 0.539), P = .085 −0.074 (−0.107, −0.040), P = <.001
Opioids 0.020 (0.014, 0.027), P = <.001 0.276 (−0.051, 0.603), P = .096 −0.065 (−0.103, −0.027), P = .001
Other chronic pain medicines 0.046 (0.039, 0.052), P = <.001 0.386 (0.048, 0.723), P = .026 −0.074 (−0.114, −0.035), P = <.001
Scotland
Other systemic NSAIDs 0.075 (−0.082, 0.233), P = .334 5.209 (3.701, 6.716), P = <.001 −0.366 (−0.565,-0.167), P = <.001
Topical NSAIDs 0.004 (−0.020, 0.028), P = .739 0.352 (0.124, 0.580), P = .004 0.025 (−0.005, 0.055), P = .099
Paracetamol −0.019 (−0.043, 0.004), P = .106 0.502 (0.277, 0.726), P = <.001 −0.053 (−0.083,-0.024), P = <.001
Opioids −0.009 (−0.018, 0.000), P = .058 0.121 (0.036, 0.207), P = .007 0.030 (0.018, 0.041), P = <.001
Other chronic pain medicines −0.046 (−0.107, 0.016), P = .138 1.305 (0.717, 1.893), P = <.001 0.067 (−0.011, 0.144), P = .090
aApproximately 10% patients were from Northern Ireland and Wales.
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with shortening in the mean duration of diclofenac prescriptions in
Denmark and significant impact when examining specific indications
for treatment.
Regulators often require a detailed overview on the use of a med-
icine among the population to assess the whether a risk minimisation
measure has been effective. Older adults were most commonly pre-
scribed diclofenac and the impact of the regulatory action tended to
be larger in these age groups who are more likely to contain patients
with specific contraindications. However, the regulatory action had
limited effect on diclofenac discontinuation rates that were highest in
The Netherlands (approximately 55%) and lowest in Scotland (approx-
imately 35%). A previous systematic review examining the impact of
FDA risk advisories in the United State suggests that such advisories
tend to be more effective at decreasing initiation of targeted medi-
cines but less effective at bringing about their discontinuation.1 These
aspects are important to examine to help understand the key drivers
of any change in prescribing, ie, whether health care professionals
simply implement the recommendations of the regulatory action in
new patients requiring treatment or actively seek to stop existing
users. We observed similar differences relating to overall diclofenac
initiation and discontinuation within the EU context suggesting these
are potentially common responses across heterogeneous health
systems. In England and Scotland, diclofenac was often prescribed as
a one-off exposure. This, in combination with a falling initiation rate,
may explain the observed fall in diclofenac discontinuation that could
be perceived as being counterintuitive.
Given the extent of regulatory actions, published evaluations of
their intended or unintended effect on health practitioner behaviour
and clinical outcomes are often lacking or subject to methodological
limitations.15 The net-benefit of the regulatory actions may be altered
if patients are switched to medicines that also cause adverse effects.
In this regard, we noted different patterns of switching to other types
of pain medicines between countries. In the case of diclofenac and
other NSAIDs, one major concern would be a switch to opioids given
the opioid epidemic that has received attention globally, and we
observed an increase in switching to opioids in Scotland only. How-
ever, changes in switching as defined in our study specifically relate to
people who discontinue diclofenac only, and the results may not be
generalisable to how opioids are prescribed among patients who had
not previously used diclofenac.
Limited impact of the 2013 EMA regulatory action for diclofenac
has been reported elsewhere in Europe. In a study examining NSAID
prescribing data from Lithuania, diclofenac prescribing remained flat
over this time and overall NSAID prescribing increased.16 However,
F IGURE 4 Trends in switching to other pain medicines in the Netherlands
MORALES ET AL. 7
significant differences should be highlighted. First, compared with
Lithuania where diclofenac had the largest NSAID market share, its
share in Denmark was as low as 7.3% by volume in 2013.17 This may
influence the perceived importance of the regulatory action in Den-
mark and downstream opportunities to publicise information. Second,
the baseline trend in diclofenac initiation in Denmark was already
falling and continued to fall following the regulatory action. It may be
more difficult to directly cause or detect significant changes in pre-
scribing trend if they are already falling (or rising) rapidly in the
intended direction, which may similarly have affected the analysis of
data from England. Lastly, only a small number of baseline time
periods from Denmark were analysed due to obvious changes in trend
throughout baseline that would have violated linear assumptions and
would have reduced the power to detect statistically significant
changes in initiation.14,18 These changes in trend within the baseline
period may have reflected the earlier safety concerns around
diclofenac discussed by the EMA's Committee for Medicinal Products
for Human Use (CHMP).19
Heterogeneity in impact may also relate to features such as the
type of warning, method of dissemination, clinical context, media cov-
erage, changes in guidelines, and public and professional perceptions
that risks are serious.20 For example, the 2004 UK risk communication
on the use of antipsychotics in dementia containing clear recommen-
dations led to greater changes in prescribing in Scotland compared
with the 2009 less specific communication in a drug bulletin.21 The
2004 risk communication was associated with a switch to typical anti-
psychotics that were considered safer at the time but were later
shown to be associated with similar risks. This suggests that monitor-
ing the impact on switching can be important to detect unintended
consequences early.
Key strengths of this study are the use of large, high quality data
sources, and a common protocol to standardise data obtained from
each data source. This study has several limitations, however. First,
our data sources do not capture over the counter use of pain medica-
tion. Second, although interrupted time series analysis is a robust
quasi-experimental design to evaluate the effects of policy interven-
tions, it examines associations around a pre-specified time period and
prescribing behaviour may be affected by other factors occurring
simultaneously at other points in time.14 However, this and other
related time series methods are recognised as a strong study design to
answer these types of questions, in a field that historically has often
used much weaker study designs to attempt to answer similar
F IGURE 5 Trends in switching to other pain medicines in England
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questions.15,22 The duration of follow up available for analysis varied
according to each data source resulting in different numbers of data
points used within regression analyses.
We demonstrate that variation in impact clearly exists, but it can
be challenging to determine whether a regulatory action is considered
successful when no established thresholds exist, or perhaps more per-
tinently, whether further regulatory action would be required to rein-
force warnings should be considered. Further information examining
what impact the regulatory action had on targeted populations in
whom diclofenac was contraindicated or cautioned would support
those decisions. The effective implementation of regulatory actions is
complex and requires input from multiple stakeholders, but there is
some evidence demonstrating which types of dissemination and com-
munication methods are most effective.20 It seems imperative that
evaluating the impact of regulatory actions should routinely account
for both intended and unintended consequences on either prescribing
health outcomes or both. In conclusion, the EMA 2013 regulatory
action targeting systemic diclofenac products reduced overall
diclofenac initiation the extent of which varied by country, whilst hav-
ing limited impact on diclofenac discontinuation and variable impact
on switching to other pain medicines.
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